Regulatory challenges surrounding Orphan drug development
Successful development plan for Orphan Drug
Commercial aspects of orphan drug development
Developing patient registries
Patient perspective
Who should Attend
CMO, CEO, Corporate Development and CSO from biotechnology companies
VPs, Presidents, Heads/Managers and Directors of (within sectors – CV, Oncology, AutoImmune and Respiratory): Therapeutic Development, (Orphan) Drug Discovery/Development, Business Unit, Marketing & Medical Affairs, External Affairs, Regulatory Affairs and Market Access From pharmaceutical companies
